Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tak-285. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 19/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 12/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 12/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | CSK | P41240 | 1/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 1/20 | 1.00 |
| ▸ | NLK | Q9UBE8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tak-285 SCHEMBL982278 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| Tak-285 SCHEMBL2747238 | 0.97 | EGFR (0.95) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| SCHEMBL20365459 | 0.95 | EGFR (0.91) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| SCHEMBL2747601 | 0.94 | EGFR (0.90) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| SCHEMBL13226160 | 0.94 | EGFR (0.90) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| Hydrochloric Acid SCHEMBL3506802 | 0.94 | EGFR (0.88) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| SCHEMBL2749523 | 0.94 | EGFR (0.90) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| SCHEMBL2749509 | 0.92 | EGFR (0.85) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| SCHEMBL15580309 | 0.92 | EGFR (0.84) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| SCHEMBL2747525 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 915 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260069596-A1 | USE OF PLK1 INHIBITOR AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCER | CARDIFF ONCOLOGY INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| US-20250275978-A1 | USE OF ONVANSERTIB AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCER | CARDIFF ONCOLOGY, INC. | 2025-09-04 | — | — | US | claimed |
| US-20250262213-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2025-08-21 | — | — | US | claimed |
| EP-4423302-A2 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | Foundation Medicine, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| CN-118414439-A | Novel kinase fusion by liquid biopsy | 基金会医学公司 | 2024-07-30 | — | — | CN | claimed |
| US-20240245634-A1 | PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT | UNITED STATES GOVERNMENT | 2024-07-25 | — | — | US | claimed |
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | L-Base Co., Ltd. (KR) | 2024-06-27 | — | — | US | claimed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| WO-2022197100-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | 주식회사 엘베이스 | 2022-09-22 | — | — | WO | claimed |
| US-20220218682-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-14 | — | — | US | claimed |
| US-20220218715-A1 | NOVEL USE OF PYRROLO-PYRIDINE DERIVATIVE COMPOUND FOR PREVENTION AND/OR TREATMENT OF CANCER | VORONOI CO., LTD. (KR) | 2022-07-14 | — | — | US | claimed |
| US-20220211706-A1 | Methods and Compositions for Treating Cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-07 | — | — | US | claimed |
| US-20220193074-A1 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-23 | — | — | US | claimed |
| US-20220145402-A1 | METHODS OF TREATING UROTHELIAL CARCINOMA | FOUNDATION MEDICINE, INC. (US) | 2022-05-12 | — | — | US | claimed |
| US-20220110940-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS | FELICITEX THERAPEUTICS, INC. | 2022-04-14 | — | — | US | claimed |
| US-11285154-B2 | Methods and compositions for treating cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-03-29 | — | — | US | claimed |
| US-20220054491-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | 2022-02-24 | — | — | US | claimed |
| EP-3955928-A1 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS | Board of Regents, The University of Texas System (US) | 2022-02-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220110940-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885ERBB3 3/4885 |
| US-20220218715-A1 | NOVEL USE OF PYRROLO-PYRIDINE DERIVATIVE COMPOUND FOR PREVENTION AND/OR TREATMENT OF CANCER | PDPK1, MAPKAPK5, PACSIN2 | EGFR 1252/4885ERBB2 403/4885ERBB3 742/4885 |
| US-20260069596-A1 | USE OF PLK1 INHIBITOR AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCER | PLK1, BRAF, KRAS | EGFR 6/4885ERBB2 18/4885ERBB3 17/4885 |
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | ALPG, SLC11A2, SGTA | EGFR 30/4885ERBB2 544/4885ERBB3 410/4885 |
| US-20250275978-A1 | USE OF ONVANSERTIB AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCER | KRAS, PLK1, NRAS | EGFR 10/4885ERBB2 14/4885ERBB3 22/4885 |
| US-20250262213-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | EGFR 4/4885ERBB2 5/4885ERBB3 6/4885 |
| US-20240245634-A1 | PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT | PCNA, MKI67, EGFR | EGFR 3/4885ERBB2 19/4885ERBB3 48/4885 |
| US-20220054491-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | EGFR 4/4885ERBB2 5/4885ERBB3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.